Business
Alvotech Publishes Prospectus in Connection with its Listing on Nasdaq Stockholm
Not to be released, published, distributed or circulated in the United States or any other jurisdiction in which it would be unlawful to do so. This press
About this update from Alvotech
[{"type":"text","content":"Not to be released, published, distributed or circulated in the United States or any other jurisdiction in which it would be unlawful to do so. This press release is for information purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities. REYKJAVIK, ICELAND AND STOCKHOLM, SWEDEN (May 8, 2025) — Alvotech (NASDAQ: ALVO, the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announces that it intends to list Swedish Depository Receipts (SDRs), equity share equivalents, on Nasdaq Stockholm. Alvotech’s board of directors and executive management believe that now is an opportune time to broaden the Company’s investor base and increase visibility among Nordic and European institutional investors, following the Company’s acquisition of Xbrane Biopharma AB’s (“Xbrane”) R&D operations, further expanding Alvotech’s development capabilities and establishing a footprint in the Swedish life science sector. Nasdaq Stockholm has assessed that Alvotech meets the applicable listing requirements, and that Nasdaq Stockholm will approve an application for admission to trading of the Company’s SDRs, subject to customary conditions, and today Alvotech publishes a prospectus for the offering of SDRs (the “Offering”). The first day of trading on Nasdaq Stockholm is expected to be May 19, 2025. “The listing on Nasdaq Stockholm affirms our ambition in biosimilars development and manufacturing globally. It is also a natural step following our recent acquisition of Xbrane’s R&D operations, which establishes a strong presence for Alvotech in the Swedish life-science industry. The listing is expected to further increase Alvotech’s recognition in the Nordic and European markets and broaden our potential shareholder base. We believe investors in Sweden, and more broadly in the Nordics and continental Europe, looking for investment opportunities in biotech will find Alvotech highly attractive, with a strong and differentiated value proposition,” said Róbert Wessman, Founder, Chairman and CEO of Alvotech. The Offering in brief The Offering will be directed solely into Sweden during an application period anticipated to be from May 9–16, 2025 (the “Application Period”).The price per SDR (the “Offering Price”) will be the lower o...